Literature DB >> 17529925

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

Guo-Xia Tong1, Luis Chiriboga, Diane Hamele-Bena, Alain C Borczuk.   

Abstract

PAX2 is a urogenital developmental transcription factor expressed in the Wolffian ducts, developing kidneys, and Müllerian ducts during embryonic stage. Its function in renal development is well documented and its clinical application in the diagnosis of lesions of renal origin has been reported recently. However, information on its role in the Müllerian-derived genital tract is sparse. In this study, we investigated the expression of PAX2 in human female genital tract using immunohistochemistry. We demonstrated that PAX2 was expressed specifically in the epithelial cells of fallopian tube, endometrial and endocervical glands, but not in the stromal tissues in these areas. PAX2 was detected in secondary Müllerian structures in the ovary, such as endometriotic and endosalpingiotic glands and rete ovarii, but not in ovarian surface epithelium, surface epithelium-derived inclusion cysts, stroma, or sex-cord-derived structures such as follicles, oocytes, and corpus luteum. In addition, PAX2 was detected in 67% of ovarian papillary serous carcinomas (N=36) but rarely in peritoneal malignant mesotheliomas, with two exceptions (N=54). Interestingly, the two PAX2-positive 'peritoneal malignant mesotheliomas' were from female patients and were positive for estrogen receptor. The significance of expression of PAX2 and estrogen receptor in these cases is under investigation. Taken together, we suggest that PAX2 is a novel Müllerian-specific epithelial marker when used in proper clinical settings. Identification of PAX2 in the majority of papillary serous carcinomas of the ovary but not in the ovarian surface epithelium or epithelium-derived inclusion cysts suggests that this malignant epithelial tumor may be directly derived from the primary or secondary Müllerian epithelium in or surrounding the ovary, rather than from the surface epithelium or its derivatives.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17529925     DOI: 10.1038/modpathol.3800827

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  26 in total

1.  Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.

Authors:  Nicolas M Monte; Kaitlyn A Webster; Donna Neuberg; Gregory R Dressler; George L Mutter
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

2.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

3.  Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin?

Authors:  Lindsey S Treviño; James R Giles; Wei Wang; Mary Ellen Urick; Patricia Ann Johnson
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

4.  Molecular characterization of 103 ovarian serous and mucinous tumors.

Authors:  Ildikó Vereczkey; Orsolya Serester; Judit Dobos; Mónika Gallai; Orsolya Szakács; Zoltán Szentirmay; Erika Tóth
Journal:  Pathol Oncol Res       Date:  2010-12-07       Impact factor: 3.201

5.  Fallopian tube correlates of ovarian serous borderline tumors.

Authors:  Anna R Laury; Gang Ning; Charles M Quick; Jonathan Bijron; Mana M Parast; Rebeca A Betensky; Sara O Vargas; Frank D McKeon; Wa Xian; Marisa R Nucci; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

6.  Lim1/LIM1 is expressed in developing and adult mouse and human endometrium.

Authors:  Louie Ye; Jemma Evans; Caroline E Gargett
Journal:  Histochem Cell Biol       Date:  2012-01-10       Impact factor: 4.304

7.  Paired box gene 2 is associated with estrogen receptor α in ovarian serous tumors: Potential theory basis for targeted therapy.

Authors:  Min Wang; Haifen Ma
Journal:  Mol Clin Oncol       Date:  2016-06-14

8.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

9.  PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Authors:  Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842

10.  MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Authors:  Cheng-Han Lee; Subbaya Subramanian; Andrew H Beck; Inigo Espinosa; Janine Senz; Shirley X Zhu; David Huntsman; Matt van de Rijn; C Blake Gilks
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.